Targeting colorectal cancer cell metabolism through development of cisplatin and metformin nano-cubosomes

about

Targeting colorectal cancer cell metabolism through development of cisplatin and metformin nano-cubosomes

Item

http://www.wikidata.org/entity/Q58778156

description

im August 2018 veröffentlichter wissenschaftlicher Artikel

@de

scientific article published on 15 August 2018

@en

wetenschappelijk artikel

@nl

наукова стаття, опублікована в серпні 2018

@uk

name

Targeting colorectal cancer ce ...... n and metformin nano-cubosomes

@en

Targeting colorectal cancer ce ...... n and metformin nano-cubosomes

@nl

type

Item

label

Targeting colorectal cancer ce ...... n and metformin nano-cubosomes

@en

Targeting colorectal cancer ce ...... n and metformin nano-cubosomes

@nl

prefLabel

Targeting colorectal cancer ce ...... n and metformin nano-cubosomes

@en

Targeting colorectal cancer ce ...... n and metformin nano-cubosomes

@nl

P1476

Targeting colorectal cancer ce ...... n and metformin nano-cubosomes

@en

P2093

Abdulaziz M Al-Mahallawi

http://www.w3.org/2001/XMLSchema#string

Mona M Saber

http://www.w3.org/2001/XMLSchema#string

P2860

A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding

Cellular and molecular mechanisms of metformin: an overview

The cancer cell's "power plants" as promising therapeutic targets: an overview

Activation of GLUT1 by metabolic and osmotic stress: potential involvement of AMP-activated protein kinase (AMPK)

Lactate promotes glioma migration by TGF-beta2-dependent regulation of matrix metalloproteinase-2.

Novel expression patterns of PI3K/Akt/mTOR signaling pathway components in colorectal cancer.

Monoolein: a review of the pharmaceutical applications.

Genetic variation in a metabolic signaling pathway and colon and rectal cancer risk: mTOR, PTEN, STK11, RPKAA1, PRKAG2, TSC1, TSC2, PI3K and Akt1.

The stimulation of glycolysis by hypoxia in activated monocytes is mediated by AMP-activated protein kinase and inducible 6-phosphofructo-2-kinase.

The efficacy of a novel, dual PI3K/mTOR inhibitor NVP-BEZ235 to enhance chemotherapy and antiangiogenic response in pancreatic cancer.

P2888

s12885-018-4727-5

P304

822

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S12885-018-4727-5

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Björn Stork

Samia A Shouman

Natasha Nassar

P577

2018-08-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1106151443

http://www.w3.org/2001/XMLSchema#string

P698

30111296

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer

metformin

cancer research

P932

6094476

http://www.w3.org/2001/XMLSchema#string